ArticleBreast cancer research and treatment2024

The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.

Christian Jackisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.